Cancer Research

Ivan Kairatov brings a wealth of experience from the front lines of biopharmaceutical innovation, where he has spent years dissecting the molecular and environmental drivers of disease. As early-onset colorectal cancer emerges as a puzzling and increasingly urgent public health crisis, his

The microscopic architecture of the human digestive tract functions as a living archive that records the subtle interplay between host genetics, environmental exposures, and the gradual progression of oncogenic transformations. For decades, the medical community has recognized that the trillions of

The rapid transformation of modern oncology is currently being defined by a sophisticated fusion of optical engineering and deep learning algorithms that are effectively replacing traditional microscopic evaluations. As the global cancer burden continues to rise, the necessity for diagnostic tools

The recent decision by the European Commission to authorize Gilead Sciences’ Trodelvy marks a transformative moment for oncology across Europe, particularly for those battling the most recalcitrant forms of breast cancer. Ivan Kairatov, a distinguished biopharma expert with a deep background in

Medical science has traditionally operated under the assumption that a brain tumor behaves with the same lethal mechanics regardless of whether the patient is male or female. Yet, statistics have long told a different story, revealing that glioblastoma is not only more common in men but also

Ivan Kairatov is a seasoned figure in the biopharmaceutical landscape, recognized for his deep-seated expertise in the intersection of nanotechnology and therapeutic innovation. With a career rooted in the rigorous environment of research and development, Kairatov has spent years navigating the